AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32682697 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRDiff (calculated as eGFRcys − eGFRcr)
Number of subjects: 9092
Study 32682697 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRDiff
Number of subjects: 9092
Study 34806530 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation (10 sessions immediately following completion of radiotherapy)
Number of subjects: 74
Study 34806530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voice rehabilitation)
Number of subjects: 74
Study 34806530 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation (10 sessions)
Number of subjects: 74
Study 34702188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir plus standard of care
Number of subjects: 691
Study 34702188 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 691
Study 33021455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam (KM)
Number of subjects: 9
Study 33021455 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone-midazolam (AM)
Number of subjects: 9
Study 33021455 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil (0.05 mg/kg SC)
Number of subjects: 9
Study 33021455 — intervention group
Group type: COMPARATOR
Intervention: Both sedation protocols
Number of subjects: 9
Study 35964045 — intervention group
Group type: EXPERIMENTAL
Intervention: Urotherapy with the SENS-U added for 3 consecutive weeks
Number of subjects: 480
Study 35964045 — intervention group
Group type: COMPARATOR
Intervention: Urotherapy with a SHAM device for 3 weeks
Number of subjects: 480
Study 35964045 — intervention group
Group type: COMPARATOR
Intervention: Urotherapy (care as usual)
Number of subjects: 480
Study 33499676 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 60
Study 33499676 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 60
Study 33499676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Number of subjects: 60
Study 35051648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP–gluten‐free diet
Number of subjects: 70
Study 35051648 — intervention group
Group type: COMPARATOR
Intervention: Usual gluten‐free diet
Number of subjects: 70
Study 34530886 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-factor prothrombin complex concentrate (PCC) 1 mL/kg (25 IU/ml of Factor IX/Kg) within 1-h post-admission
Number of subjects: 0
Study 34530886 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 0.9% as a placebo
Number of subjects: 0
Study 34530886 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-factor prothrombin complex concentrate (PCC)
Number of subjects: 0
Study 32640755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing with FeelBreathe (FB) device
Number of subjects: 18
Study 32640755 — intervention group
Group type: COMPARATOR
Intervention: Oronasal breathing
Number of subjects: 18
Study 34615719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacnotuzumab + gemcitabine + carboplatin (gem-carbo)
Number of subjects: 49
Study 34615719 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + carboplatin (gem-carbo)
Number of subjects: 49
Study 34615719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacnotuzumab + gem-carbo
Number of subjects: 49
Study 34615719 — intervention group
Group type: COMPARATOR
Intervention: Gem-carbo
Number of subjects: 49
Study 35061598 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy with additional Akin correction
Number of subjects: 145
Study 35061598 — intervention group
Group type: COMPARATOR
Intervention: Scarf osteotomy without additional Akin correction
Number of subjects: 145
Study 33221428 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant-tensioning single-bundle (RT-SB) ACL reconstruction
Number of subjects: 67
Study 33221428 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 67
Study 33053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50 IU/kg body mass)
Number of subjects: 31
Study 33053823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 31
Study 35279289 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia
Number of subjects: 474
Study 35279289 — intervention group
Group type: COMPARATOR
Intervention: cold blood cardioplegia
Number of subjects: 474
Study 33934982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) oxygen therapy
Number of subjects: 200
Study 33934982 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy through a simple oxygen mask
Number of subjects: 200
Study 32560744 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate agents for COVID-19 treatment (specific candidates not detailed)
Number of subjects: 16
Study 32560744 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 16
Study 35015750 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV‐chair
Number of subjects: 74
Study 35015750 — intervention group
Group type: COMPARATOR
Intervention: Manual treatment maneuvers
Number of subjects: 74
Study 34279996 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted plasma Lp(a) levels
Number of subjects: 408403
Study 34279996 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted LPA expression levels
Number of subjects: 408403
Study 34619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention program (1-hour individualized session with a cardiology nurse)
Number of subjects: 60
Study 34619115 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 33181655 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and multi-disciplinary management including rehabilitation exercise, diet adjustment, multi-drug evaluation, acupoint massage in TCM, and patient education for 12 months
Number of subjects: 320
Study 33181655 — intervention group
Group type: COMPARATOR
Intervention: Routine management for basic diseases
Number of subjects: 320
Study 35553967 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g prunes/day
Number of subjects: 106
Study 35553967 — intervention group
Group type: EXPERIMENTAL
Intervention: 100g prunes/day
Number of subjects: 106
Study 35553967 — intervention group
Group type: COMPARATOR
Intervention: 0g prunes/day (control)
Number of subjects: 106
Study 33228550 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital 10 Hz rTMS
Number of subjects: 18
Study 33228550 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 35272599 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 vaccine (CoronaVac)
Number of subjects: 101
Study 34401364 — intervention group
Group type: EXPERIMENTAL
Intervention: blended CBT (bCBT)
Number of subjects: 0
Study 34401364 — intervention group
Group type: COMPARATOR
Intervention: face-to-face CBT (ftf CBT)
Number of subjects: 0
Study 36459828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 382
Study 36459828 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 382
Study 36459828 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study 32942920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Biomicroscopy (Quantel Aviso with 50 MHz transducer)
Number of subjects: 15
Study 34981712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients
Number of subjects: 34
Study 34981712 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Control group)
Number of subjects: 34
Study 33421840 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 101
Study 33421840 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 101
Study 32585226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration (10 L/min by face mask)
Number of subjects: 114
Study 32585226 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 114
Study 32585226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 114
Study 35386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal depressive symptoms
Number of subjects: 0
Study 35386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depressive symptoms
Number of subjects: 0
Study 35386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried status
Number of subjects: 0
Study 35386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal substance use (smoking or alcohol consumption)
Number of subjects: 0
Study 35386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 0
Study 35386031 — intervention group
Group type: COMPARATOR
Intervention: Risk factors for postpartum depression
Number of subjects: 0
Study 33835071 — intervention group
Group type: EXPERIMENTAL
Intervention: Group X (flared crest module and buttress thread design)
Number of subjects: 40
Study 33835071 — intervention group
Group type: COMPARATOR
Intervention: Group A (parallel crest module and V-shaped thread design)
Number of subjects: 40
Study 32963294 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3-PUFA enriched chicken-meat and eggs
Number of subjects: 161
Study 32963294 — intervention group
Group type: COMPARATOR
Intervention: Control chicken-meat and eggs
Number of subjects: 161
Study 35770251 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (5 μg each, 2 doses, 21 days apart)
Number of subjects: 3000
Study 35770251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 35770251 — intervention group
Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine
Number of subjects: 3000
Study 33855996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy and foot reflexology added to standard of care
Number of subjects: 41
Study 33855996 — intervention group
Group type: COMPARATOR
Intervention: Standard of care management during brachytherapy
Number of subjects: 41
Study 36089374 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery (PI)
Number of subjects: 80
Study 36089374 — intervention group
Group type: COMPARATOR
Intervention: Turbine handpiece (TH)
Number of subjects: 80
Study 32386922 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 32386922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32386922 — intervention group
Group type: EXPERIMENTAL
Intervention: First drug administration
Number of subjects: 0
Study 36054046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional 1,550-nm erbium:glass laser (NAFL)
Number of subjects: 21
Study 36054046 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency microneedling (RFMN)
Number of subjects: 21
Study 34759559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization with 4 ml of 0.75% ropivacaine (Group B)
Number of subjects: 40
Study 34759559 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal nebulization with 4 ml of saline (Group C)
Number of subjects: 40
Study 36333692 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (5000 units weekly for 3 months)
Number of subjects: 60
Study 36333692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32311349 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomass-fueled cookstove intervention
Number of subjects: 1805
Study 32311349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1805
Study 36106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (S/V) treatment
Number of subjects: 8787
Study 36106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted sacubitril/valsartan (rS/V) treatment
Number of subjects: 8787
Study 36106548 — intervention group
Group type: COMPARATOR
Intervention: Conventional HF treatment (non-S/V)
Number of subjects: 8787
Study 36106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 8787
Study 36106548 — intervention group
Group type: EXPERIMENTAL
Intervention: HF hospitalizations
Number of subjects: 8787
Study 36106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency room visits without hospitalization
Number of subjects: 8787
Study 32976864 — intervention group
Group type: EXPERIMENTAL
Intervention: L-GrAFT7 risk score
Number of subjects: 3423
Study 32976864 — intervention group
Group type: EXPERIMENTAL
Intervention: L-GrAFT7 risk score (highest tertile)
Number of subjects: 3423
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC 18.7 mg/g
Number of subjects: 17
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC 10.8 mg/g
Number of subjects: 17
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC 5.3 mg/g
Number of subjects: 17
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC 2.3 mg/g
Number of subjects: 17
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC 1.3 mg/g
Number of subjects: 17
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC ≤ 2.3 mg/g
Number of subjects: 17
Study 32221696 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC ≥ 5.3 mg/g
Number of subjects: 17
Study 34919072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiscale pyramid two-dimensional convolutional neural network for automated segmentation
Number of subjects: 20
Study 35896533 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) with D-cycloserine (DCS)
Number of subjects: 192
Study 35896533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Imaginal Exposure (PE) with D-cycloserine (DCS)
Number of subjects: 192
Study 35896533 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 192
Study 35896533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 32584196 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue recipe (BHR)
Number of subjects: 60
Study 32584196 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue recipe (BHR) combined with estradiol valerate
Number of subjects: 60
Study 32584196 — intervention group
Group type: EXPERIMENTAL
Intervention: BHR in rats with kidney deficiency-related blood stasis
Number of subjects: 60
Study 35147131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii multiglycosides tablets (1-1.5 mg/kg body weight/d, orally) in addition to angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Number of subjects: 20
Study 35147131 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Number of subjects: 20
Study 33328115 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabby intervention (online conversational agent)
Number of subjects: 528
Study 33328115 — intervention group
Group type: COMPARATOR
Intervention: Control group (letter listing preconception risks)
Number of subjects: 528
Study 35300759 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based risk prediction model combining pre/intraoperative risk factors and intraoperative vital signs; evaluated using logistic regression analysis and LSTM model.
Number of subjects: 839
Study 35300759 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated annealing algorithm to adjust intraoperative vital signs.
Number of subjects: 839
Study 35300759 — intervention group
Group type: COMPARATOR
Intervention: Multivariable Logistic regression model, random forest model, and LSTM model including vital signs only.
Number of subjects: 839
Study 35534435 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose for prostate cancer diagnosis
Number of subjects: 174
Study 33197657 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 ng) + Vitamin E (400 IU)
Number of subjects: 70
Study 33197657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32171422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8)
Number of subjects: 310
Study 32171422 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8)
Number of subjects: 310
Study 34895993 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF surgery with bony endplates preserved (Group A)
Number of subjects: 0
Study 34895993 — intervention group
Group type: COMPARATOR
Intervention: ACDF surgery with bony endplates removed (Group B)
Number of subjects: 0
Study 34619574 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (n=10)
Number of subjects: 20
Study 34619574 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n=10)
Number of subjects: 20
Study 33292423 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention to improve job satisfaction of general practice teams
Number of subjects: 0
Study 33292423 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35324230 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐PE (Web‐based Prolonged Exposure Therapy)
Number of subjects: 74
Study 35324230 — intervention group
Group type: COMPARATOR
Intervention: Present‐Centered Therapy (PCT)
Number of subjects: 74
Study 35324230 — intervention group
Group type: COMPARATOR
Intervention: PCT (Present‐Centered Therapy)
Number of subjects: 74
Study 616389173 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 80
Study 616389173 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 80
Study 35785889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 1
Study 34880973 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic examination combined with ultrasound imaging based on intelligent algorithm processing (Cascade RCNN model algorithm)
Number of subjects: 80
Study 34880973 — intervention group
Group type: COMPARATOR
Intervention: Simple use of endoscopy (control group)
Number of subjects: 80
Study 34880973 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional convolutional neural network (CNN) model
Number of subjects: 80
Study 35723120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS combined with FES
Number of subjects: 60
Study 35723120 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS
Number of subjects: 60
Study 35723120 — intervention group
Group type: COMPARATOR
Intervention: FES
Number of subjects: 60
Study 33709134 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Insecurity (WI)
Number of subjects: 716
Study 33121439 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy
Number of subjects: 0
Study 33121439 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence monitoring and quality of life assessments using validated self-reported instruments (EQ-5D-5L)
Number of subjects: 0
Study 36455222 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cap‐assisted endoscopic mucosal resection (mEMR-C)
Number of subjects: 79
Study 36455222 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 79
Study 33168393 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 1385
Study 33168393 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 1385
Study 36482599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy with Dermatophagoides Farinae Drops for 3 months
Number of subjects: 60
Study 36482599 — intervention group
Group type: COMPARATOR
Intervention: Mometasone Furoate nasal spray for 3 months
Number of subjects: 60
Study 36482599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy
Number of subjects: 60
Study 36482599 — intervention group
Group type: COMPARATOR
Intervention: Mometasone Furoate nasal spray
Number of subjects: 60
Study 33081570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane plus epirubicin
Number of subjects: 2945
Study 33081570 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and epirubicin
Number of subjects: 2945
Study 33081570 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs plus doxorubicin
Number of subjects: 2945
Study 32272345 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised end-to-end CNN architecture for segmentation
Number of subjects: 947
Study 34340637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (n = 18)
Number of subjects: 56
Study 34340637 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (n = 18)
Number of subjects: 56
Study 34340637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of aerobic exercise and computerized cognitive training (n = 20)
Number of subjects: 56
Study 34340637 — intervention group
Group type: COMPARATOR
Intervention: Control (Aerobic exercise or cognitive training alone)
Number of subjects: 56
Study 32009435 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture Button (SB)
Number of subjects: 97
Study 32009435 — intervention group
Group type: COMPARATOR
Intervention: Syndesmotic Screw (SS)
Number of subjects: 97
Study 37932788 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide (ETEL)
Number of subjects: 62
Study 37932788 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (ALFA)
Number of subjects: 62
Study 33483093 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session treatment
Number of subjects: 53
Study 33483093 — intervention group
Group type: COMPARATOR
Intervention: Weekly treatment
Number of subjects: 53
Study 34146225 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based facial analysis tool (3D model)
Number of subjects: 16
Study 34146225 — intervention group
Group type: COMPARATOR
Intervention: Direct measurements on human subjects' faces
Number of subjects: 16
Study 34146225 — intervention group
Group type: COMPARATOR
Intervention: Measurements on 2D photographs
Number of subjects: 16
Study 34146225 — intervention group
Group type: COMPARATOR
Intervention: Measurements on 3D models of face scans
Number of subjects: 16